Found 2 hits Enz. Inhib. hit(s) with Target = 'Beta-2 adrenergic receptor' and Ligand = 'BDBM200750' Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
Beta-2 adrenergic receptor
(Homo sapiens (Human)) | BDBM200750
(US9233108, 15 | US9757383, Example 15)Show SMILES CN(CCCn1c2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2oc1=O)[C@H]1CC[C@@H](CC1)OC(=O)C1(C)c2ccccc2Oc2ccccc12 |wU:35.42,wD:13.13,32.35,(3.58,2.63,;5.09,2.31,;5.57,.85,;4.54,-.3,;5.01,-1.76,;3.98,-2.91,;4.3,-4.41,;5.64,-5.18,;5.64,-6.72,;4.3,-7.49,;4.3,-9.03,;5.64,-9.8,;5.64,-11.34,;6.97,-12.11,;8.3,-11.34,;6.97,-13.65,;5.64,-14.42,;5.64,-15.96,;6.97,-16.73,;6.97,-18.27,;8.3,-15.96,;9.64,-16.73,;10.97,-15.96,;12.3,-16.73,;10.97,-14.42,;9.64,-13.65,;8.3,-14.42,;2.97,-6.72,;2.97,-5.18,;1.82,-4.15,;2.45,-2.75,;1.68,-1.41,;6.12,3.45,;7.63,3.13,;8.66,4.28,;8.18,5.74,;6.68,6.06,;5.65,4.92,;9.21,6.89,;8.74,8.35,;7.23,8.67,;9.77,9.5,;8.24,9.71,;10.03,11.01,;8.85,12,;9.12,13.52,;10.57,14.05,;11.75,13.06,;11.48,11.54,;12.66,10.55,;12.39,9.03,;13.57,8.04,;13.31,6.53,;11.86,6,;10.68,6.99,;10.95,8.51,)| Show InChI InChI=1S/C44H46N4O8/c1-44(32-8-3-5-10-37(32)55-38-11-6-4-9-33(38)44)42(52)54-29-15-13-28(14-16-29)47(2)22-7-23-48-34-19-12-27(24-39(34)56-43(48)53)25-45-26-36(50)30-17-20-35(49)41-31(30)18-21-40(51)46-41/h3-6,8-12,17-21,24,28-29,36,45,49-50H,7,13-16,22-23,25-26H2,1-2H3,(H,46,51)/t28-,29-,36-/m0/s1 | PDB MMDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 1.5 | n/a | n/a | n/a | n/a | n/a | n/a |
Almirall, S.A.
US Patent
| Assay Description The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are ov... |
US Patent US9757383 (2017)
BindingDB Entry DOI: 10.7270/Q2HX1FSN |
More data for this Ligand-Target Pair | |
Beta-2 adrenergic receptor
(Homo sapiens (Human)) | BDBM200750
(US9233108, 15 | US9757383, Example 15)Show SMILES CN(CCCn1c2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2oc1=O)[C@H]1CC[C@@H](CC1)OC(=O)C1(C)c2ccccc2Oc2ccccc12 |wU:35.42,wD:13.13,32.35,(3.58,2.63,;5.09,2.31,;5.57,.85,;4.54,-.3,;5.01,-1.76,;3.98,-2.91,;4.3,-4.41,;5.64,-5.18,;5.64,-6.72,;4.3,-7.49,;4.3,-9.03,;5.64,-9.8,;5.64,-11.34,;6.97,-12.11,;8.3,-11.34,;6.97,-13.65,;5.64,-14.42,;5.64,-15.96,;6.97,-16.73,;6.97,-18.27,;8.3,-15.96,;9.64,-16.73,;10.97,-15.96,;12.3,-16.73,;10.97,-14.42,;9.64,-13.65,;8.3,-14.42,;2.97,-6.72,;2.97,-5.18,;1.82,-4.15,;2.45,-2.75,;1.68,-1.41,;6.12,3.45,;7.63,3.13,;8.66,4.28,;8.18,5.74,;6.68,6.06,;5.65,4.92,;9.21,6.89,;8.74,8.35,;7.23,8.67,;9.77,9.5,;8.24,9.71,;10.03,11.01,;8.85,12,;9.12,13.52,;10.57,14.05,;11.75,13.06,;11.48,11.54,;12.66,10.55,;12.39,9.03,;13.57,8.04,;13.31,6.53,;11.86,6,;10.68,6.99,;10.95,8.51,)| Show InChI InChI=1S/C44H46N4O8/c1-44(32-8-3-5-10-37(32)55-38-11-6-4-9-33(38)44)42(52)54-29-15-13-28(14-16-29)47(2)22-7-23-48-34-19-12-27(24-39(34)56-43(48)53)25-45-26-36(50)30-17-20-35(49)41-31(30)18-21-40(51)46-41/h3-6,8-12,17-21,24,28-29,36,45,49-50H,7,13-16,22-23,25-26H2,1-2H3,(H,46,51)/t28-,29-,36-/m0/s1 | PDB MMDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 1.5 | n/a | n/a | n/a | n/a | n/a | 25 |
ALMIRALL, S.A.
US Patent
| Assay Description The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are ov... |
US Patent US9233108 (2016)
BindingDB Entry DOI: 10.7270/Q23J3BSN |
More data for this Ligand-Target Pair | |